Medi-Vet SA, Lausanne, Switzerland.
Medi-Vet SA, Lausanne, Switzerland.
Vet Anaesth Analg. 2022 May;49(3):313-322. doi: 10.1016/j.vaa.2022.01.004. Epub 2022 Jan 31.
To evaluate the efficacy of a perineural injection of dexmedetomidine combined with ropivacaine for reducing postoperative methadone requirements in dogs after tibial plateau levelling osteotomy (TPLO).
A prospective, clinical, randomized and blinded trial.
A total of 58 client-owned dogs.
Ultrasound-guided midfemoral sciatic and inguinal femoral nerve blocks with ropivacaine (1 mg kg per nerve block) combined with either dexmedetomidine (0.5 μg kg per nerve block; group DEX) or the same volume of saline (group CON) were performed in dogs undergoing TPLO. Pain was assessed 30 minutes, 2 hours and then every 4 hours for 24 hours after surgery with a validated pain scale (4AVet). Meloxicam (0.15 mg kg) was administered intravenously (IV) at recovery. Rescue methadone (0.2 mg kg IV) was administered if a score ≥ 6 (maximal score 18) was recorded and the number of postoperative doses was analysed by Fisher exact tests. The study was performed in parallel at a Veterinary Teaching Hospital (VTH) and a private Veterinary Referral Centre (VRC).
Dogs received a total of 22 and 31 postoperative doses of methadone in groups DEX (14 doses at VRC, eight doses at VTH) and CON (28 doses at VRC, three doses at VTH), respectively. Overall, there was no difference in the postoperative rescue analgesia requirements between groups (p = 0.244). At the VRC, dogs received less methadone (p = 0.026) in group DEX compared with group CON, whereas at the VTH, there was no difference between groups (p = 0.216).
Perineural dexmedetomidine combined with ropivacaine did not reduce postoperative methadone requirements in dogs after TPLO, but results may differ from one centre to another. This discrepancy might be linked to variations in clinical practices and questions the validity of results obtained from single-centre randomized controlled trials but applied to different clinical settings.
评估在胫骨平台切开复位术(TPLO)后,对犬施行股神经和坐骨神经周围注射右美托咪定联合罗哌卡因,以减少术后美沙酮需求的效果。
前瞻性、临床、随机、双盲试验。
58 只患犬。
58 只接受 TPLO 的患犬接受了超声引导下的股神经和股神经腹股沟内注射,每根神经阻滞用罗哌卡因(1mg/kg),同时注射右美托咪定(0.5μg/kg;DEX 组)或等量生理盐水(CON 组)。术后 30 分钟、2 小时以及此后每 4 小时使用经过验证的疼痛量表(4AVet)评估疼痛。术后在恢复时,静脉(IV)给予美洛昔康(0.15mg/kg)。如果记录的分数≥6(最大分数 18),则给予吗啡(0.2mg/kg IV)解救,并通过 Fisher 确切检验分析术后剂量数。该研究在一家兽医教学医院(VTH)和一家私人兽医转诊中心(VRC)同时进行。
DEX 组(VRC 共 14 剂,VTH 共 8 剂)和 CON 组(VRC 共 28 剂,VTH 共 3 剂)的犬分别接受了 22 次和 31 次术后吗啡解救剂量。总体而言,两组之间术后解救镇痛需求无差异(p=0.244)。在 VRC,DEX 组犬接受的吗啡较少(p=0.026),而在 VTH,两组之间无差异(p=0.216)。
TPLO 后,犬施行周围神经内注射右美托咪定联合罗哌卡因不能减少术后美沙酮需求,但结果可能因中心而异。这种差异可能与临床实践的差异有关,对单中心随机对照试验的结果提出了质疑,但适用于不同的临床环境。